Effects of a DA2/α2 agonist and a β1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 3, 1999, Pages 321-326

  Masson, Serge ^a   Masseroli, Marco ^a   Fiordaliso, Fabio ^a   Calvillo, Laura ^a   D'Aquila, Silvia ^a   Bernasconi, Roberto ^a   Garrido, Gabino ^a   Torri, Mauro ^a   Razzetti, Roberta ^b   Bongrani, Stefano ^b   Latini, Roberto ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Catecholamines; CHF 1024; Delapril; Heart; Left ventricular dysfunction; Left ventricular remodeling; Metoprolol; Myocardial infarction

Indexed keywords

5,6 DIHYDROXY 2 METHYL AMINOTETRALINE HYDROCHLORIDE; 5,6 DIHYDROXY 2 METHYLAMINOTETRALIN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; METOPROLOL; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NORADRENALIN;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; ANIMAL; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG POTENTIATION; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; MALE; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; URINE;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; HEMODYNAMIC PROCESSES; MALE; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, DOPAMINE D2; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 0032586738     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199909000-00001     Document Type: Article

References (20)

1. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
2. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991;260:H1406-14.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
4. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI 3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
5. 2 agonist and a β-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 1998;31:601-8.
6. Anonymous. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/ American Heart Association Task Force on Practical Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-98.
7. Anonymous. The treatment of heart failure: Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J 1997;18:736-53.
8. Goldstein DS, Feuerstein G, Izzo JL Jr, Kopin IJ, Keiser HR. II. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 1981;28:467-75.
9. Porzio S, Masseroli M, Messori A, et al. A simple, automatic method for morphometric analysis of the left ventricle in rats with myocardial infarction. J Pharmacol Toxicol Methods 1995;33: 221-9.
10. Puccini P, Zanelli U, Spinabelli D, et al. In vivo metabolism of CHF 1035: a chiral aminotetraline, in the rat. Pharmacol Res 1997; 35:209.
11. Crippa G, Umile A, Carrara GC, Reyes AJ. First clinical experience with the new oral dopaminergic CHF 1035 in congestive heart failure. J Heart Failure 1995;2:590.
12. Chiba K, Moriyama S, Ishigai Y, Fukuzawa A, Irie K, Shibano T. Lack of correlation of hypotensive effects with prevention of cardiac hypertrophy by perindopril after ligation of rat coronary artery. Br J Pharmacol 1994;112:837-42.
13. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
14. Gay RG. Early and late effects of captopril treatment after large myocardial infarction in rats. J Am Coll Cardiol 1990;16:967-77.
15. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators. N Engl J Med 1992;327:669-77.
16. Capasso JM, Li P, Zhang X, Anversa P. Heterogeneity of ventricular remodeling after acute myocardial infarction in rats. Am J Physiol 1992;262:H486-95.
17. van Veldhuisen DJ, Brodde OE, van Gilst WH, et al. Relation between myocardial β-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril. Cardiovasc Res 1995;30:386-93.
18. Francis GS, Parks R, Cohn JN. The effects of bromocriptine in patients with congestive heart failure. Am Heart J 1983;106:100-6.
19. Manolis AJ, Olympios C, Sifaki M, et al. Suppressing sympathetic activation in congestive heart failure: a new therapeutic strategy. Hypertension 1995;26:719-24.
20. Missale C, Lombardi C, De Cotiis R, Memo M, Carruba MO, Spano PF. Dopaminergic receptor mechanisms modulating the renin-angiotensin system and aldosterone secretion: an overview. J Cardiovasc Pharmacol 1989;14(suppl 8):S29-39.